How do practicing clinicians manage Helicobacter pylori-related gastrointestinal diseases in Germany? A survey of gastroenterologists and family practitioners

被引:26
作者
Breuer, T
Sudhop, T
Goodman, KJ
Graham, DY
Malfertheiner, P
机构
[1] Univ Magdeburg, Dept Internal Med, D-39120 Magdeburg, Germany
[2] Univ Texas, Sch Publ Hlth, Houston, TX USA
[3] Univ Bonn, Dept Clin Pharmacol, D-5300 Bonn, Germany
[4] Baylor Coll Med, Dept Med, Vet Adm Med Ctr, Houston, TX 77030 USA
关键词
D O I
10.1046/j.1523-5378.1998.08027.x
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background. Since the bacterium H. pylori was identified in 1982, overwhelming evidence has implicated it as the causal factor in the occurrence and relapse of peptic ulcer disease. The major objective of this study was to examine the extent to which physicians recognize H. pylori as a causal agent in peptic ulcer disease or as potential cofactor in other gastrointestinal diseases, and the extent to which this knowledge has influenced diagnostic and therapeutic practices. Materials and Methods. Using a national mail survey in Germany in September 1995, 1197 family practitioners and 1197 gastroenterologists were selected for the study. Results. Of the surveyed physicians, 756 (32%) responded. Family practitioners treated almost 50% of their patients with initial presentation of suspected ulcer disease without ordering further diagnostic tests. More than 25% of the family practitioners and 14% of the gastroenterologists reported that they do not treat diagnosed H. pylori infection in the first presentation of duodenal ulcer. At the time we conducted the study, 22% of responding family practitioners and 5% of responding gastroenterologists treated the first presentation of H. pylori-positive ulcer disease with regimens determined to be ineffective according to the available literature. Conclusions. Gastroenterologists preferred to treat H. pylori infection when the associated disease was one for which a causal relationship had been more clearly established, while family practitioners showed less discrimination. In order to provide optimal therapy aimed at minimizing the course and consequences of H. pylori-related diseases, researchers in the field must ensure continuous dissemination of current knowledge.
引用
收藏
页码:1 / 8
页数:8
相关论文
共 43 条
  • [1] [Anonymous], 1994, IARC Monogr Eval Carcinog Risks Hum, V61, P1
  • [2] [Anonymous], 1994, NIH Consens Statement, V12, P1
  • [3] BABBS C, 1995, GUT S1, V37, P347
  • [4] GASTRITIS AND CAMPYLOBACTER-PYLORI IN HEALTHY, ASYMPTOMATIC VOLUNTEERS
    BARTHEL, JS
    WESTBLOM, TU
    HAVEY, AD
    GONZALEZ, F
    EVERETT, ED
    [J]. ARCHIVES OF INTERNAL MEDICINE, 1988, 148 (05) : 1149 - 1151
  • [5] REGRESSION OF PRIMARY GASTRIC LYMPHOMA OF MUCOSA-ASSOCIATED LYMPHOID-TISSUE TYPE AFTER CURE OF HELICOBACTER-PYLORI INFECTION
    BAYERDORFFER, E
    NEUBAUER, A
    RUDOLPH, B
    THIEDE, C
    LEHN, N
    EIDT, S
    STOLTE, M
    [J]. LANCET, 1995, 345 (8965): : 1591 - 1594
  • [6] BAYERDORFFER E, 1992, EUR J GASTROEN HEPAT, V4, P697
  • [7] DOUBLE-BLIND TRIAL OF OMEPRAZOLE AND AMOXICILLIN TO CURE HELICOBACTER-PYLORI INFECTION IN PATIENTS WITH DUODENAL-ULCERS
    BAYERDORFFER, E
    MIEHLKE, S
    MANNES, GA
    SOMMER, A
    HOCHTER, W
    WEINGART, J
    HELDWEIN, W
    KLANN, H
    SIMON, T
    SCHMITT, W
    BASTLEIN, E
    EIMILLER, A
    HATZ, R
    LEHN, N
    DIRSCHEDL, P
    STOLTE, M
    [J]. GASTROENTEROLOGY, 1995, 108 (05) : 1412 - 1417
  • [8] SHORT-TERM LOW-DOSE TRIPLE THERAPY FOR THE ERADICATION OF HELICOBACTER-PYLORI
    BAZZOLI, F
    ZAGARI, RM
    FOSSI, S
    POZZATO, P
    ALAMPI, G
    SIMONI, P
    SOTTILI, S
    RODA, A
    RODA, E
    [J]. EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 1994, 6 (09) : 773 - 777
  • [9] BOEKEMA PJ, 1996, GUT, V39, pA62
  • [10] Breuer T., 1996, Gut, V39, pA21